Sugi Predict

Sugi Predict / Compounds / SCHEMBL2453138

SCHEMBL2453138

SCHEMBL2453138

COc1cc2ncnc(Cl)c2cc1OC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.54
▸ PIK3CA P42336 2/20 0.54
▸ PIK3CB P42338 2/20 0.54
▸ PIK3CG P48736 2/20 0.54
▸ PDE4B Q07343 3/20 0.54
▸ PDE4A P27815 2/20 0.54
▸ PDE4C Q08493 2/20 0.54
▸ PDE4D Q08499 2/20 0.54
▸ EGFR P00533 12/20 0.51
▸ ERBB2 P04626 6/20 0.51
▸ BRAF P15056 1/20 0.49
▸ EPHB4 P54760 2/20 0.49
▸ RIPK2 O43353 1/20 0.49
▸ RET P07949 1/20 0.49
▸ MET P08581 1/20 0.49
▸ EPHB2 P29323 1/20 0.49
▸ TEC P42680 1/20 0.49
▸ EPHA4 P54764 1/20 0.49
▸ BTK Q06187 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465790 1.00 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL29465791 1.00 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL665187 1.00 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL28983490 0.95 PIK3CD (0.48) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL29834734 0.94 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL29834791 0.94 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL24714039 0.90 ENPP1 (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL30822064 0.90 ENPP1 (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPDE4B
SCHEMBL22598590 0.90 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL29465805 0.90 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPIK3CGEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 — — US disclosed
EP-4506343-A1 HETEROARYL DERIVATIVE AND USE THEREOF Voronoi Inc. (KR) 2025-02-12 — — EP disclosed
US-20240383923-A1 HETEROARYL DERIVATIVE AND USE THEREOF VORONOI INC. (KR) 2024-11-21 — — US disclosed
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC. (KR) 2024-07-25 — — US disclosed
CN-114026083-B Heterocyclic inhibitors of tyrosine kinases 德州大学系统董事会 2024-07-09 — — CN disclosed
EP-4392423-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Arthrosi Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN disclosed
WO-2024059169-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-03-21 — — WO disclosed
CN-117693505-A Heteroaryl derivative compounds and uses thereof 沃若诺伊公司 2024-03-12 — — CN disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 — — EP disclosed
EP-1667992-A1 QUINAZOLINE DERIVATIVES Astrazeneca AB (SE) 2006-06-14 — — EP disclosed
EP-1660479-A1 PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS Astrazeneca AB (SE) 2006-05-31 — — EP disclosed
US-20050215574-A1 4-anilino quinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2005-09-29 — — US disclosed
US-20050165035-A1 Quinazoline derivatives ASTRAZENECA AB 2005-07-28 — — US disclosed
WO-2005030765-A1 QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS ASTRAZENECA AB (SE) 2005-04-07 — — WO disclosed
WO-2005028470-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-03-31 — — WO disclosed
WO-2005028469-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-03-31 — — WO disclosed
WO-2005012290-A1 PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2005-02-10 — — WO disclosed
EP-1487806-A1 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS Astrazeneca AB (SE) 2004-12-22 — — EP disclosed
WO-2003082831-A1 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS ASTRAZENECA AB (SE) 2003-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215574-A1 4-anilino quinazoline derivatives as antiproliferative agents ERBB2, ERBB4, EGFR PIK3CD 108/4885PIK3CA 41/4885PIK3CB 152/4885
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF ERBB2, EGFR, ERBB3 PIK3CD 133/4885PIK3CA 112/4885PIK3CB 150/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 PIK3CD 1122/4885PIK3CA 185/4885PIK3CB 745/4885
US-20050165035-A1 Quinazoline derivatives ERBB2, EGFR, ERBB4 PIK3CD 385/4885PIK3CA 299/4885PIK3CB 574/4885
US-20240383923-A1 HETEROARYL DERIVATIVE AND USE THEREOF ERBB2, ERBB3, EGFR PIK3CD 195/4885PIK3CA 129/4885PIK3CB 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.